JP4590417B2 - Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 - Google Patents

Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 Download PDF

Info

Publication number
JP4590417B2
JP4590417B2 JP2006549676A JP2006549676A JP4590417B2 JP 4590417 B2 JP4590417 B2 JP 4590417B2 JP 2006549676 A JP2006549676 A JP 2006549676A JP 2006549676 A JP2006549676 A JP 2006549676A JP 4590417 B2 JP4590417 B2 JP 4590417B2
Authority
JP
Japan
Prior art keywords
npc1l1
binding
cholesterol
cells
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006549676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007526998A (ja
JP2007526998A5 (https=
Inventor
ガルシア−カルボ，マルガリータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2007526998A publication Critical patent/JP2007526998A/ja
Publication of JP2007526998A5 publication Critical patent/JP2007526998A5/ja
Application granted granted Critical
Publication of JP4590417B2 publication Critical patent/JP4590417B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006549676A 2004-01-16 2005-01-14 Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 Expired - Fee Related JP4590417B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53734104P 2004-01-16 2004-01-16
PCT/US2005/001469 WO2005069900A2 (en) 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof

Publications (3)

Publication Number Publication Date
JP2007526998A JP2007526998A (ja) 2007-09-20
JP2007526998A5 JP2007526998A5 (https=) 2008-02-28
JP4590417B2 true JP4590417B2 (ja) 2010-12-01

Family

ID=34807095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549676A Expired - Fee Related JP4590417B2 (ja) 2004-01-16 2005-01-14 Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法

Country Status (6)

Country Link
US (1) US7901893B2 (https=)
EP (1) EP1723414A4 (https=)
JP (1) JP4590417B2 (https=)
CA (1) CA2553769C (https=)
MX (1) MXPA06008124A (https=)
WO (1) WO2005069900A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN100471835C (zh) 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
WO2005069900A2 (en) 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
EP1893222A4 (en) * 2005-06-15 2010-07-07 Merck Sharp & Dohme ANTI-HYPERCHOLESTERINAMIC COMPOUNDS
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP1986489A2 (en) 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
EP2173893A4 (en) * 2007-06-28 2010-07-21 Merck Sharp & Dohme USE OF MDCK CELLS IN THE ASSESSMENT OF CHOLESTEROL MODULATORS
CN101580871B (zh) * 2008-05-13 2013-06-05 中国科学院上海生命科学研究院 基于分析npc1l1蛋白亚细胞定位变化筛选降胆固醇新药的方法
CN102869382A (zh) * 2010-06-10 2013-01-09 (株)Ad生物技 通过抑制肠内胆固醇吸收而抑制高脂血症和肥胖症的组合物
WO2016179212A1 (en) * 2015-05-05 2016-11-10 Albert Einstein College Of Medicine, Inc. Antibody therapeutics against filovirus infections and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561227A (en) * 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
ES2107548T3 (es) * 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
FI960095L (fi) * 1993-07-09 1996-01-09 Schering Corp Menetelmä atsetidinonien syntetitoimiseksi
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5618707A (en) * 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU8286998A (en) * 1997-07-03 1999-01-25 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Genes for niemann-pick type c disease
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
HK1039487B (en) 1998-12-07 2005-08-12 Merck Sharp & Dohme Corp. Process for the synthesis of azetidinones
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
ATE549412T1 (de) 1999-04-05 2012-03-15 Schering Corp Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon
WO2000063703A1 (en) * 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1273657A4 (en) 2000-03-24 2005-04-06 Takeda Pharmaceutical NEW PROTEIN, METHOD FOR ITS PRODUCTION AND ITS USE
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EE05453B1 (et) * 2001-03-28 2011-08-15 Schering Corporation Protsess asetidinoonvahehendite valmistamiseks
WO2003100094A2 (en) 2002-05-23 2003-12-04 Devgen Nv Method for determining the influence of a compound on cholesterol transport
CA2492017A1 (en) * 2002-07-19 2004-01-29 Schering Corporation Npc1l1 (npc3) and methods of use thereof
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040137467A1 (en) * 2002-07-19 2004-07-15 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
RU2345089C2 (ru) 2002-08-06 2009-01-27 Санофи-Авентис Дойчланд Гмбх ОЧИЩЕННЫЙ 145 кДа-БЕЛОК, СПОСОБНЫЙ СВЯЗЫВАТЬ ХОЛЕСТЕРИН И/ИЛИ ИНГИБИТОРЫ ПОГЛОЩЕНИЯ ХОЛЕСТЕРИНА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ОЧИСТКИ И ПРИМЕНЕНИЕ 145 кДа-БЕЛКА
EP1562605A4 (en) 2002-10-08 2006-07-12 Massachusetts Inst Technology COMPOUNDS FOR MODULATING CHOLESTER INTRANSPORT
WO2005069900A2 (en) 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
CA2579790A1 (en) 2004-07-30 2006-02-09 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CA2553769A1 (en) 2005-08-04
CA2553769C (en) 2011-01-04
EP1723414A2 (en) 2006-11-22
JP2007526998A (ja) 2007-09-20
US7901893B2 (en) 2011-03-08
WO2005069900A3 (en) 2006-06-08
WO2005069900B1 (en) 2006-08-03
US20100009461A1 (en) 2010-01-14
WO2005069900A2 (en) 2005-08-04
EP1723414A4 (en) 2008-03-26
MXPA06008124A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
JP4590417B2 (ja) Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
JP2010142238A (ja) Ｎｐｃ１ｌ１（ｎｐｃ３）およびその使用方法
JP2010252798A (ja) Ｎｐｃ１ｌ１（ｎｐｃ３）およびその使用方法
US20120079616A1 (en) Npc1l1 (npc3) and methods of use thereof
WO2001077325A1 (fr) Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
US20080227125A1 (en) Secreted Polypeptide Species Reduced in Cardiovascular Disorders
JP2007501605A (ja) 心血管疾患に関連する分泌ポリペプチド種
US8212016B2 (en) NPC1L1 orthologues
US20070009955A1 (en) Secreted polypeptide species associated with cardiovascular disorders
EP1403281B1 (en) Novel ligand and dna thereof
US20040137467A1 (en) NPC1L1 (NPC3) and methods of use thereof
JP2007513063A (ja) 心臓血管障害に関連する分泌ポリペプチド種
JP2003310281A (ja) 新規タンパク質およびそのｄｎａ
WO2003072780A1 (fr) Nouvelles protéines, leurs adn et leur utilisation
CA2691267A1 (en) Use of mdck cells in the evaluation of cholesterol modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100831

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100913

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130917

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees